These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34628933)

  • 1. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
    Li J; Shui Z; Ouyang Q
    Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
    Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
    BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
    Hu ZY; Yan M; Xiong H; Ran L; Zhong J; Luo T; Sun T; Xie N; Liu L; Yang X; Xiao H; Li J; Liu B; Ouyang Q
    BMC Med; 2023 Jun; 21(1):226. PubMed ID: 37365596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
    Xie N; Liu L; Tian C; Hu Z; Ouyang Q
    Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
    Zhu W; Wu J; Cui M; Zhang L
    Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
    Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
    Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
    Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
    Yang C; Shangguan C; Lou G; Qu Q
    Ann Palliat Med; 2022 Jan; 11(1):332-338. PubMed ID: 35144424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
    Dai S; Zhang Y; Tan X; Luo F; Yan X
    Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study.
    Zhang J; Meng Y; Wang B; Wang L; Cao J; Tao Z; Li T; Yao W; Hu X
    Front Oncol; 2022; 12():775081. PubMed ID: 35321427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.